Czarny Piotr, Białek Katarzyna, Ziółkowska Sylwia, Strycharz Justyna, Barszczewska Gabriela, Sliwinski Tomasz
Department of Medical Biochemistry, Medical University of Lodz, 92-216 Lodz, Poland.
Laboratory of Medical Genetics, Faculty of Biology and Environmental Protection, University of Lodz, 90-236 Lodz, Poland.
J Pers Med. 2021 Mar 1;11(3):167. doi: 10.3390/jpm11030167.
Recent studies imply that there is a tight association between epigenetics and a molecular mechanism of major depressive disorder (MDD). Epigenetic modifications, i.e., DNA methylation, post-translational histone modification and interference of microRNA (miRNA) or long non-coding RNA (lncRNA), are able to influence the severity of the disease and the outcome of the therapy. This article summarizes the most recent literature data on this topic, i.e., usage of histone deacetylases as therapeutic agents with an antidepressant effect and miRNAs or lncRNAs as markers of depression. Due to the noteworthy potential of the role of epigenetics in MDD diagnostics and therapy, we have gathered the most relevant data in this area.
近期研究表明,表观遗传学与重度抑郁症(MDD)的分子机制之间存在紧密联系。表观遗传修饰,即DNA甲基化、组蛋白翻译后修饰以及微小RNA(miRNA)或长链非编码RNA(lncRNA)的干扰,能够影响疾病的严重程度和治疗效果。本文总结了关于该主题的最新文献数据,即组蛋白去乙酰化酶作为具有抗抑郁作用的治疗药物的应用,以及miRNA或lncRNA作为抑郁症标志物的研究。鉴于表观遗传学在MDD诊断和治疗中具有显著的潜在作用,我们收集了该领域最相关的数据。